Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Volitionrx (VNRX) over the last 8 years, with Q3 2025 value amounting to $199407.0.

  • Volitionrx's Cash & Equivalents fell 9631.69% to $199407.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $199407.0, marking a year-over-year decrease of 9631.69%. This contributed to the annual value of $3.3 million for FY2024, which is 8425.26% down from last year.
  • Volitionrx's Cash & Equivalents amounted to $199407.0 in Q3 2025, which was down 9631.69% from $2.3 million recorded in Q2 2025.
  • Volitionrx's 5-year Cash & Equivalents high stood at $33.1 million for Q1 2021, and its period low was $199407.0 during Q3 2025.
  • Over the past 5 years, Volitionrx's median Cash & Equivalents value was $11.8 million (recorded in 2024), while the average stood at $13.9 million.
  • Per our database at Business Quant, Volitionrx's Cash & Equivalents skyrocketed by 9076.0% in 2023 and then crashed by 9631.69% in 2025.
  • Over the past 5 years, Volitionrx's Cash & Equivalents (Quarter) stood at $20.6 million in 2021, then crashed by 47.2% to $10.9 million in 2022, then surged by 90.76% to $20.7 million in 2023, then plummeted by 84.25% to $3.3 million in 2024, then tumbled by 93.89% to $199407.0 in 2025.
  • Its Cash & Equivalents was $199407.0 in Q3 2025, compared to $2.3 million in Q2 2025 and $2.6 million in Q1 2025.